Jerry Jialun Meng

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Agouron Pharmaceuticals, Inc., Pfizer Corporation, Sugen Incorporated. Active years: 2005-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jerry Jialun Meng. Retrieved from https://idiyas.com/inventor/jerry-jialun-meng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 66.7

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 134(Granted Patents)

Company Filing History:

3 out of 174

Agouron Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2005-2014

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8785632 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2014-07-22),

2. 8106197 - Aminoheteroaryl compounds as protein kinase inhibitors (2012-01-31),

3. 8080556 - 2-amino pyrimidine compounds as potent HSP-90 inhibitors (2011-12-20),

4. 7858643 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2010-12-28),

5. 7230098 - Aminoheteroaryl compounds as protein kinase inhibitors (2007-06-12),

6. 6964957 - Fused pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity (2005-11-15),

Title: Innovations of Jerry Jialun Meng: Pioneering Protein Kinase Inhibitors

Introduction: Jerry Jialun Meng, an accomplished inventor based in San Diego, CA, has made significant contributions to the field of medicinal chemistry. With a portfolio of six patents to his name, he has focused on developing compounds that serve as potent inhibitors for various protein kinases, particularly in the treatment of abnormal cell growth disorders such as cancer.

Latest Patents: Among his noteworthy inventions, Jerry holds patents for "Enantiomerically Pure Aminoheteroaryl Compounds as Protein Kinase Inhibitors" and "Aminoheteroaryl Compounds as Protein Kinase Inhibitors." The former details the synthesis and application of specifically structured compounds that inhibit the c-Met protein kinase, which is crucial for addressing issues related to abnormal cell growth. His second patent emphasizes the potential of aminopyridine and aminopyrazine compounds in the same context, showcasing their utility as effective inhibitors of c-MET.

Career Highlights: Throughout his career, Jerry has made impactful strides while collaborating with renowned companies such as Pfizer Corporation and Agouron Pharmaceuticals, Inc. His research and development efforts have been instrumental in advancing therapeutic options and understanding the mechanisms of various diseases.

Collaborations: In his journey, Jerry has had the opportunity to work alongside talented colleagues, including Pei-Pei Kung and Jingrong Jean Cui. Their collaborative efforts have contributed to his innovative research and the success of his patent applications.

Conclusion: Jerry Jialun Meng's work exemplifies the spirit of innovation within the pharmaceutical industry. His commitment to creating compounds that target vital cellular mechanisms positions him as a leading inventor and a driving force in the pursuit of effective treatments for serious health conditions. With a solid foundation of patents and a collaborative spirit, Jerry continues to push the boundaries of medical research and innovation.

Profile summary based on public USPTO records.